Gefitinib loaded folate decorated bovine serum albumin conjugated carboxymethyl-betacyclodextrin nanoparticles enhance drug delivery and attenuate autophagy in folate receptor-positive cancer cells

Journal of Nanobiotechnology

Volumn 12, Issue 1, 2014, Pages

  Shi, Yijie ^a   Su, Chang ^a   Cui, Wenyu ^b   Li, Hongdan ^a   Liu, Liwei ^a   Feng, Bo ^a   Liu, Ming ^a   Su, Rongjian ^a   Zhao, Liang ^a  

^a JINZHOU MEDICAL UNIVERSITY   (China)

^b National Vaccine and Serum Institute   (China)

Author keywords

Bovine serum albumin; Carboxymethyl Cyclodextrin; Folate; Folate receptors; Gefitinib; Nanoparticles

Indexed keywords

BODY FLUIDS; CELL DEATH; CONTROLLED DRUG DELIVERY; CYCLODEXTRINS; DISEASES; MAMMALS; MOLECULAR BIOLOGY; NANOPARTICLES; ORGANIC ACIDS; SURFACE PLASMON RESONANCE; TUMORS;

BOVINE SERUM ALBUMINS; CARBOXYMETHYL; FOLATE; FOLATE RECEPTOR; GEFITINIB;

TARGETED DRUG DELIVERY;

BOVINE SERUM ALBUMIN; CARBOXYMETHYL BETA CYCLODEXTRIN; CASPASE 3; FOLATE RECEPTOR; GEFITINIB; NANOPARTICLE; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; BETA CYCLODEXTRIN DERIVATIVE; CARBOXYMETHYL-BETA-CYCLODEXTRIN; FOLIC ACID; QUINAZOLINE DERIVATIVE;

ARTICLE; AUTOPHAGY; CANCER CELL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DISPERSITY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; DRUG STABILITY; ENDOCYTOSIS; HUMAN; HUMAN CELL; HYDROPHOBICITY; IN VITRO STUDY; IN VIVO STUDY; INFRARED SPECTROSCOPY; INTERNALIZATION; NANOMEDICINE; PARTICLE SIZE; PHOTON CORRELATION SPECTROSCOPY; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SURFACE CHARGE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; HELA CELL LINE; METABOLISM; MOLECULARLY TARGETED THERAPY;

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENTS; AUTOPHAGY; BETA-CYCLODEXTRINS; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; FOLATE RECEPTORS, GPI-ANCHORED; FOLIC ACID; HELA CELLS; HUMANS; MOLECULAR TARGETED THERAPY; NANOPARTICLES; QUINAZOLINES; SERUM ALBUMIN, BOVINE; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 84920762565     PISSN: None     EISSN: 14773155     Source Type: Journal    
DOI: 10.1186/s12951-014-0043-7     Document Type: Article

References (43)

1. Iafisco M, Delgado-Lopez JM, Varoni EM, Tampieri A, Rimondini L, Gomez-Morales J, Prat M: Cell Surface Receptor Targeted Biomimetic Apatite Nanocrystals for Cancer Therapy. Small 2013, 9(22):3834-3844.
2. Chen H, Zhao Y, Wang H, Nie G, Nan K: Co-delivery strategies based on multifunctional nanocarriers for cancer therapy. Curr Drug Metab 2012, 13(8):1087-1096.
3. Danhier F, Feron O, Préat V: To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 2010, 148(2):135-146.
4. Torchilin VP: Multifunctional nanocarriers. Adv Drug Deliv Rev 2012, 64:302-315.
5. Gao H, Zhang Q, Yu Z, He Q: Cell-penetrating peptide-based intelligent liposomal systems for enhanced drug delivery. Curr Pharm Biotechnol 2014, 15:210-219.
6. Mattheolabakis G, Taoufik E, Haralambous S, Roberts ML, Avgoustakis K: In vivo investigation of tolerance and antitumor activity of cisplatin-loaded PLGA-mPEG nanoparticles. Eur J Pharm Biopharm 2009, 71(2):190-195.
7. Hyung Park J, Kwon S, Lee M, Chung H, Kim JH, Kim YS, Park RW, Kim IS, Bong Seo S, Kwon IC, Young Jeong S: Self-assembled nanoparticles based on glycol chitosan bearing hydrophobic moieties as carriers for Gefitiniborubicin: in vivo biodistribution and anti-tumor activity. Biomaterials 2006, 27(1):119-126.
8. Yu Z, Schmaltz RM, Bozeman TC, Paul R, Rishel MJ, Tsosie KS, Hecht SM: Selective Tumor Cell Targeting by the Disaccharide Moiety of Bleomycin. J Am Chem Soc 2013, 135:2883-2886.
9. William P, Vincent M, Maureen Z, Jennifer D, Katerina P, Inderpal S, Bhuvanesh S, Robert H, Valerie R, Lucinda F, Elaine M, Doris K, Richard W, Mark K, Harold V: EGF receptor genemutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 2004, 101(36):13306-13311.
10. Morabito A, Costanzo R, Rachiglio AM, Pasquale R, Sandomenico C, Franco R, Montanino A, De Lutio E, Rocco G, Normanno N: Activity of Gefitinib in a Non-Small-Cell Lung Cancer Patient with Both Activating and Resistance EGFR Mutations. J Thorac Oncol 2013, 8(7):e59-e60.
11. Ozao-Choy J, Ma G, Kao J, Wang GX, Meseck M, Sung M, Schwartz M, Divino CM, Pan PY, Chen SH: The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 2009, 69(6):2514-2522.
12. Sordella R, Bell DW, Haber DA, Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004, 305(5687):1163-1167.
13. Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn WD, Morse D, Abraham S, Rahman A, Liang C, Lostritto R, Baird A, Pazdur R: United States Food and Drug Administration drug approval summary gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004, 10(4):1212-1218.
14. Kakuta T, Takashima Y, Nakahata M, Otsubo M, Yamaguchi H, Harada A: Preorganized Hydrogel: Self-Healing Properties of Supramolecular Hydrogels Formed by Polymerization of Host-Guest-Monomers that Contain Cyclodextrins and Hydrophobic Guest Groups. Adv Mater 2013, 25(20):2849-2853.
15. Loftsson T, Brewster ME: Cyclodextrins as functional excipients: methods to enhance complexation efficiency. J Pharm Sci 2012, 101(9):3019-3032.
16. Loftsson T, Duchêne D: Cyclodextrins and their pharmaceutical applications. Int J Pharm 2007, 329:1-11.
17. Kurkov SV, Loftsson T: Cyclodextrins. Int J Pharm 2013, 453(1):167-180.
18. Szente L, Szemán J: Cyclodextrins in Analytical Chemistry: Host-Guest Type Molecular Recognition. Anal Chem 2013, 85(17):8024-8030.
19. Del Valle EM: Cyclodextrins and their uses: a review. Process Biochem 2004, 39(9):1033-1046.
20. Agasti SS, Liong M, Tassa C, Chung HJ, Shaw SY, Lee H, Weissleder R: Supramolecular host-guest interaction for labeling and detection of cellular biomarkers. Angew Chem Int Ed Engl 2012, 51(2):450-454.
21. Dorokhin D, Hsu SH, Tomczak N, Reinhoudt DN, Huskens J, Velders AH, Vancso GJ: Fabrication and luminescence of designer surface patterns with β-cyclodextrin functionalized quantum dots via multivalent supramolecular coupling. ACS Nano 2010, 4:137-142.
22. Zhang B, Jin H, Li Y, Chen B, Liu S, Shi D: Bioinspired synthesis of gadolinium-based hybrid nanoparticles as MRI blood pool contrast agents with high relaxivity. J Mater Chem 2012, 22(29):14494-14501.
23. Sun SK, Dong L, Cao Y, Sun H, Yan X: Fabrication of multifunctional Gd2O3/Au hybrid nanoprobe via a one-step approach for near-infrared fluorescence and magnetic resonance multimodal imaging in vivo. Anal Chem 2013, 85(17):8436-8441.
24. Zhang B, Li Q, Yin P, Rui Y, Qiu Y, Wang Y, Shi D: Ultrasound-triggered BSA/SPION hybrid nanoclusters for liver-specific magnetic resonance imaging. ACS Appl Mater Interfaces 2012, 4(12):6479-6486.
25. Zhang B, Wang X, Liu F, Cheng Y, Shi D: Effective reduction of nonspecific binding by surface engineering of quantum dots with bovine serum albumin for cell-targeted imaging. Langmuir 2012, 28(48):16605-16613.
26. Cagle PT, Zhai QJ, Murphy L, Low PS: Folate receptor in adenocarcinoma and squamous cell carcinoma of the lung: potential target for folatelinked therapeutic agents. Arch Pathol Lab Med 2013, 137(2):241-244.
27. Chen C, Ke J, Zhou XE, Yi W, Brunzelle JS, Li J, Yong EL, Xu HE, Melcher K: Structural basis for molecular recognition of folic acid by folate receptors. Nature 2013, 500(7463):486-489.
28. Leamon CP: Folate-targeted drug strategies for the treatment of cancer. Curr Opin Investig Drugs 2008, 9(12):1277-1286.
29. Coney LR, Tomassetti A, Carayannopoulos L, Frasca V, Kamen BA, Colnaghi MI, Zurawski VR Jr: Cloning of a tumor-associated antigen: MOv18 and MOv19 antibodies recognize a folate-binding protein. Cancer Res 1991, 51(22):6125-6132.
30. Weitman SD, Frazier KM, Kamen BA: The folate receptor in central nervous system malignancies of childhood. J Neurooncol 1994, 21(2):107-112.
31. Campbell IG, Jones TA, Foulkes WD, Trowsdale J: Folate-binding protein is a marker for ovarian cancer. Cancer Res 1991, 51(19):5329-5338.
32. Reddy JA, Low PS: Folate-mediated targeting of therapeutic and imaging agents to cancers. Crit Rev Ther Drug Carrier Syst 1998, 15(6):587-627.
33. Chen H, Ahn R, Van den Bossche J, Thompson DH, O'Halloran TV: Folate-mediated intracellular drug delivery increases the anticancer efficacy of nanoparticulate formulation of arsenic trioxide. Mol Cancer Ther 2009, 8(7):1955-1963.
34. Chu BC, Kramer FR, Orgel LE: Synthesis of an amplifiable reporter RNA for bioassays. Nucleic Acids Res 1986, 14(14):5591-5603.
35. Ghosh SS, Kao PM, McCue AW, Chappelle HL: Use of maleimide-thiol coupling chemistry for efficient syntheses of oligonucleotide-enzyme conjugate hybridization probes. Bioconjug Chem 1990, 1(1):71-76.
36. Staros JV, Wright RW, Swingle DM: Enhancement by N-hydroxysulfosuccinimide of water-soluble carbodiimide-mediated coupling reactions. Anal Biochem 1986, 156(1):220-222.
37. Khalil SK, El-Feky GS, El-Banna ST, Khalil WA: Preparation and evaluation of warfarin-β-cyclodextrin loaded chitosan nanoparticles for transdermal delivery. Carbohydr Polym 2012, 90(3):1244-1253.
38. Joo KI, Xiao L, Liu S, Liu Y, Lee CL, Conti PS, Wong MK, Li Z, Wang P: Crosslinked multilamellar liposomes for controlled delivery of anticancer drugs. Biomaterials 2013, 34(12):3098-3109.
39. Schroeder BR, Ghare MI, Bhattacharya C, Paul R, Yu Z, Zaleski PA, Bozeman TC, Rishel MJ, Hecht SM: The disaccharide moiety of bleomycin facilitates uptake by cancer cells. J Am Chem Soc 2014, 136(39):13641-13656.
40. Qi R, Liu S, Chen J, Xiao H, Yan L, Huang Y, Jing X: Biodegradable copolymers with identical cationic segments and their performance in siRNA delivery. J Control Release 2012, 159(2):251-260.
41. Xiao H, Qi R, Liu S, Hu X, Duan T, Zheng Y, Huang Y, Jing X: Biodegradable polymer-cisplatin(IV) conjugate as a pro-drug of cisplatin(II). Biomaterials 2011, 32(30):7732-7739.
42. Song Y, Shi W, Chen W, Li X, Ma H: Fluorescent carbon nanodots conjugated with folic acid for distinguishing folate-receptor-positive cancer cells from normal cells. J Mater Chem 2012, 22(25):12568-12573.
43. Feng D, Song Y, Shi W, Li X, Ma H: Distinguishing Folate-Receptor-Positive Cells from Folate-Receptor-Negative Cells Using a Fluorescence Off-On Nanoprobe. Anal Chem 2013, 85(13):6530-6535.